News | Radiology Business | December 06, 2021

Stevens will Join the Board of Directors in 2022, and Michael Klein will remain Chairman of iCAD Board

iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Board of Directors appointed Stacey Stevens as iCAD’s President and Chief Executive Officer (CEO), effective March 1, 2022.

Stacy Stevens


December 6, 2021 — iCAD, Inc., a global medical technology leader providing innovative cancer detection and therapy solutions, today announced that its Board of Directors appointed Stacey Stevens as iCAD’s President and Chief Executive Officer (CEO), effective March 1, 2022. Stevens, who has served as the Company’s President since 2019, will also join the Company’s Board of Directors. Michael Klein, who currently serves as the Company Chairman and CEO, will continue to serve as Chairman of iCAD’s Board of Directors.

“On behalf of the entire Board of Directors, I would like to congratulate Ms. Stevens on this appointment. It has been a privilege to work closely with her for the past three years, as she brings a relentless focus on leading change and a proven track record of driving growth and innovation. I look forward to continued interaction in her new capacity as CEO,” said Klein, Chairman and CEO of iCAD, Inc. “We are currently at an important inflection point, with the recent launch of several first-in-kind technologies and the Company’s increasing focus on enterprise sales on the Detection side of the business, and with the expansion of Xoft in emerging applications, such as the treatment of brain tumors, on the Therapy side of the business. I am confident that with Ms. Stevens at the helm, iCAD and its technologies will continue to transform the landscape of cancer detection and therapy and accelerate the value we bring to all of our stakeholders.”

“I am honored to have the opportunity to lead the company at this exciting time in our growth,” said Stevens, President of iCAD, Inc. “iCAD’s technologies offer clinical performance superiority, workflow improvements, and a broad healthcare economic value proposition for both clinicians and patients. We are enhancing patient care and optimizing outcomes, which ultimately translates to improving, extending, and saving lives. I look forward to working with our talented and passionate team to advance the Company as we continue to evolve our business and technology, drive sustained market leadership, and create additional significant shareholder value.”

“The Board of Directors would also like to thank Mr. Klein for his significant contributions as CEO over the last three years,” said Nate Dalton, iCAD’s Lead Independent Director. “Under his leadership, the Company’s robust portfolio of cancer detection and therapy technologies has expanded, offering strong value propositions for clinicians, patients, and our shareholders. With iCAD now well positioned for future growth, we are confident that Ms. Stevens will strengthen iCAD’s position as an industry leader providing medical technologies that are improving the landscape of cancer detection and therapy, while delivering consistent returns to our shareholders.”

An accomplished executive with more than 20 years of marketing, strategy and sales experience, Stevens has served as iCAD’s President since 2019. Prior to that, she served as Executive Vice President and Chief Strategy and Commercial Officer from 2017-2019. Ms. Stevens joined iCAD in 2006 as Senior Vice President of Marketing and Strategy. Prior to her tenure at iCAD, she held numerous commercial leadership positions across multiple business units at Philips Healthcare. Ms. Stevens earned a Bachelor of Arts Degree in Political Science from the University of New Hampshire, and an MBA from Boston University’s Questrom School of Business. Ms. Stevens was named one of CEO Today’s “Businesswomen of the Year” in 2021.

For more information: www.icadmed.com

 


Related Content

News | RSNA

July 23, 2024 — Professional registration is open for RSNA 2024, the world’s largest radiology forum. This year’s theme ...

Time July 23, 2024
arrow
News | Artificial Intelligence

July 22, 2024 — Healthcare artificial intelligence (AI) systems provider, Qure.ai, has announced its receipt of a Class ...

Time July 22, 2024
arrow
News | Radiology Education

July 19, 2024 — Core tactics to address the current medical imaging and radiation therapy workforce shortage and build ...

Time July 19, 2024
arrow
News | ASTRO

July 18, 2024 — The members of the American Society for Radiation Oncology (ASTRO) recently elected five new officers to ...

Time July 18, 2024
arrow
News | Flat Panel Displays

July 17, 2024 — LG Electronics (LG) is accelerating its B2B medical device business, expanding its lineup of diagnostic ...

Time July 17, 2024
arrow
Feature | Imaging Technology News - ITN

Be sure to check out the latest digital edition of Imaging Technology News (ITN), featuring the Mobile C-arm Systems ...

Time July 11, 2024
arrow
News | Radiation Oncology

July 11, 2024 — The American Society for Radiation Oncology (ASTRO) issued the following statement from Jeff M ...

Time July 11, 2024
arrow
News | Prostate Cancer

July 11, 2024 — GE HealthCare’s MIM Software, a global provider of medical imaging analysis and artificial intelligence ...

Time July 11, 2024
arrow
News | Artificial Intelligence

July 11, 2024 — Artificial Intelligence (AI) tools can play a key role in medical imaging if radiologists trust in their ...

Time July 11, 2024
arrow
Feature | Radiation Oncology | By Christine Book

News emerging from several leading organizations and vendors in the radiation therapy arena came in at a fast pace in ...

Time July 09, 2024
arrow
Subscribe Now